{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:54:03Z","timestamp":1773075243537,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00108-018-0538-7","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:08:35Z","timestamp":1547197715000},"page":"10-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diagnose und Therapie der Nierenbeteiligung bei Plasmazellerkrankungen","Diagnosis and treatment of kidney involvement in plasma cell diseases"],"prefix":"10.1007","volume":"60","author":[{"given":"V.","family":"G\u00f6decke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Br\u00e4sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"issue":"3","key":"538_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"L Knudsen","year":"2000","unstructured":"Knudsen L, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol 65(3):175\u2013181","journal-title":"Eur J Haematol"},{"issue":"1","key":"538_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et\u00a0al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21\u201333. \n                    https:\/\/doi.org\/10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"538_CR3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","volume":"59","author":"SH Nasr","year":"2012","unstructured":"Nasr SH, Valeri AM, Sethi S et\u00a0al (2012) Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 59(6):786\u2013794. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2011.12.028","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"538_CR4","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.18632\/oncotarget.23412","volume":"9","author":"N Steiner","year":"2018","unstructured":"Steiner N, G\u00f6bel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E (2018) Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget 9(2):2344\u20132356","journal-title":"Oncotarget"},{"issue":"22","key":"538_CR5","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung N, Bridoux F, Hutchison C et\u00a0al (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120(22):4292\u20134295","journal-title":"Blood"},{"issue":"11","key":"538_CR6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/ajh.24528","volume":"91","author":"T Kourelis","year":"2016","unstructured":"Kourelis T, Nasr S, Dispenzieri A et\u00a0al (2016) Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 91(11):1123\u20131128","journal-title":"Am J Hematol"},{"issue":"12","key":"538_CR7","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos M, Palumbo A et\u00a0al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. lancet Oncol 15(12):e538\u2013e548","journal-title":"lancet Oncol"},{"issue":"2","key":"538_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2215\/CJN.08640811","volume":"7","author":"S Nasr","year":"2012","unstructured":"Nasr S, Valeri A, Cornell L et\u00a0al (2012) Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a\u00a0single institution. Clin J Am Soc Nephrol 7(2):231\u2013239","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"538_CR9","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","volume":"24","author":"M Gertz","year":"2009","unstructured":"Gertz M, Leung N, Lacy M et\u00a0al (2009) Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 24(10):3132\u20133137","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"538_CR10","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2215\/CJN.11161111","volume":"7","author":"N Leung","year":"2012","unstructured":"Leung N, Gertz M, Kyle R et al (2012) Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol 7(12):1964\u20131968","journal-title":"Clin J Am Soc Nephrol"},{"key":"538_CR11","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1038\/bcj.2014.56","volume":"4","author":"H Sugihara","year":"2014","unstructured":"Sugihara H, Chihara D, Seike K et al (2014) Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment. Blood Cancer\u00a0J 4:e235\u2013e235","journal-title":"Blood Cancer J"},{"issue":"1","key":"538_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrneph.2011.168","volume":"8","author":"C Hutchison","year":"2011","unstructured":"Hutchison C, Batuman V, Behrens J et\u00a0al (2011) The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8(1):43\u201351","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"538_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2215\/CJN.00560117","volume":"13","author":"N Leung","year":"2018","unstructured":"Leung N, Drosou M, Nasr S (2018) Dysproteinemias and glomerular disease. Clin J Am Soc Nephrol 13(1):128\u2013139","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"538_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/MNH.0000000000000201","volume":"25","author":"S Sethi","year":"2016","unstructured":"Sethi S, Fervenza F, Rajkumar SV (2016) Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens 25(2):127\u2013137","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"13","key":"538_CR15","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"M Dimopoulos","year":"2016","unstructured":"Dimopoulos M, Sonneveld P, Leung N et al (2016) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J\u00a0Clin Oncol 34(13):1544\u20131557","journal-title":"J Clin Oncol"},{"issue":"9","key":"538_CR16","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","volume":"32","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Musto P, Caers J et\u00a0al (2018) European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 32(9):1883\u20131898","journal-title":"Leukemia"},{"issue":"11","key":"538_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.mayocp.2013.08.002","volume":"88","author":"S Sethi","year":"2013","unstructured":"Sethi S, Rajkumar SV (2013) Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 88(11):1284\u20131293","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"538_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1681\/ASN.2010080857","volume":"22","author":"C Hutchison","year":"2011","unstructured":"Hutchison C, Cockwell P, Stringer S et al (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J\u00a0Am Soc Nephrol 22(6):1129\u20131136","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"538_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1681\/ASN.2006080821","volume":"18","author":"C Hutchison","year":"2007","unstructured":"Hutchison C, Cockwell P, Reid S et\u00a0al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J\u00a0Am Soc Nephrol 18(3):886\u2013895","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"538_CR20","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMc1101834","volume":"364","author":"B Burnette","year":"2011","unstructured":"Burnette B, Leung N, Rajkumar SV (2011) Renal improvement in myeloma with bortezomib plus plasma exchange. N\u00a0Engl J Med 364(24):2365\u20132366","journal-title":"N Engl J Med"},{"issue":"11","key":"538_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","volume":"143","author":"W Clark","year":"2005","unstructured":"Clark W, Stewart AK, Rock G et\u00a0al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"5","key":"538_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5414\/CP202245","volume":"53","author":"X Yu","year":"2015","unstructured":"Yu X, Gan L, Wang Z, Dong B, Chen X (2015) Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther 53(5):391\u2013397","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"538_CR23","first-page":"149","volume":"31","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Padmanabhan A, Aqui N et al (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the american society for apheresis: the seventh special issue. J\u00a0Clin Apher 31(3):149\u2013162","journal-title":"J Clin Apher"},{"issue":"4","key":"538_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2215\/CJN.04590908","volume":"4","author":"C Hutchison","year":"2009","unstructured":"Hutchison C, Bradwell A, Cook M et al (2009) Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 4(4):745\u2013754","journal-title":"Clin J Am Soc Nephrol"},{"key":"538_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1745-6215-9-55","volume":"9","author":"C Hutchison","year":"2008","unstructured":"Hutchison C, Cook M, Heyne N et\u00a0al (2008) European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 9:55\u201355","journal-title":"Trials"},{"issue":"21","key":"538_CR26","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.2017.17924","volume":"318","author":"F Bridoux","year":"2017","unstructured":"Bridoux F, Carron P, Pegourie B et al (2017) Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA 318(21):2099\u20132110","journal-title":"JAMA"},{"issue":"10","key":"538_CR27","doi-asserted-by":"publisher","first-page":"e0140463","DOI":"10.1371\/journal.pone.0140463","volume":"10","author":"M Rousseau Gagnon","year":"2015","unstructured":"Rousseau Gagnon M, Agharazii M, De Serres S, Desmeules S (2015) Effectiveness of haemodiafiltration with heat sterilized high-flux polyphenylene HF dialyzer in reducing free light chains in patients with myeloma cast nephropathy. PLoS ONE 10(10):e140463\u2013e140463","journal-title":"PLoS ONE"},{"issue":"26","key":"538_CR28","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","volume":"126","author":"R Sayed","year":"2015","unstructured":"Sayed R, Wechalekar A, Gilbertson J et\u00a0al (2015) Natural history and outcome of light chain deposition disease. Blood 126(26):2805\u20132810","journal-title":"Blood."},{"issue":"6","key":"538_CR29","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","volume":"26","author":"SMS Herrmann","year":"2011","unstructured":"Herrmann SMS, Gertz M, Stegall M et al (2011) Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant 26(6):2032\u20132036","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"538_CR30","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2016.12.023","volume":"69","author":"T Le","year":"2017","unstructured":"Le T, Wolf J, Peralta C, Webber A (2017) Kidney transplantation for kidney failure due to multiple myeloma: case reports. Am J Kidney Dis 69(6):858\u2013862","journal-title":"Am J Kidney Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0538-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0538-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0538-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:15:07Z","timestamp":1578701707000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0538-7"}},"subtitle":["Renale Beteiligung bei multiplem Myelom und monoklonalen Gammopathien","Renal involvement in multiple myeloma and monoclonal gammopathies"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["538"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0538-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"11 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Koenecke: Beratungst\u00e4tigkeit f\u00fcr AbbVie, Amgen, BMS, Roche. V.\u00a0G\u00f6decke, J.J.\u00a0Schmidt, J.H.\u00a0Br\u00e4sen und H.\u00a0Haller geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}